Last reviewed · How we verify
ONO-2506PO
At a glance
| Generic name | ONO-2506PO |
|---|---|
| Sponsor | Ono Pharmaceutical Co. Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan (PHASE2)
- A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
- Effects of ONO-2506PO in Patients With Alzheimer's Disease (PHASE2)
- Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ONO-2506PO CI brief — competitive landscape report
- ONO-2506PO updates RSS · CI watch RSS
- Ono Pharmaceutical Co. Ltd portfolio CI